JLE

Médecine

MENU

What to think of cancer immunotherapy? (Part 1) Volume 16, issue 3, Mars 2020

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4
Author
Hématologue, professeur émérite de thérapeutique (Université Sorbonne-Paris Cité)
* Correspondance

The incidence of cancer in France continues to increase, but it is fortunately striking to note that paradoxically mortality decreases even more clearly. The arrival of two new therapeutic methods has really revolutionized strategies: The so-called “targeted” therapies (which we will discuss in another article) and immunotherapy. We propose here to approach cancer immunotherapy: How to explain it? What resources are currently available to cancer specialists? What are the current and expected results? What are the risks?